Kallikrein 13 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9UKR3 |
---|---|
Clone Names | 4040202 |
Gene ID | 26085 |
---|---|
Other Names | Kallikrein-13, 3421-, Kallikrein-like protein 4, KLK-L4, KLK13, KLKL4 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6332b was selected from the C-term region of human KLK13. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | KLK13 |
---|---|
Synonyms | KLKL4 |
Cellular Location | Secreted. |
Tissue Location | Expressed in prostate, breast, testis and salivary gland |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. Expression of KLK13 is regulated by steroid hormones and may be useful as a marker for breast cancer.
References
Kapadia, C., et al., Biochem. Biophys. Res. Commun. 323(3):1084-1090 (2004).Petraki, C.D., et al., Prostate Cancer Prostatic Dis. 6(3):223-227 (2003).Chang, A., et al., Br. J. Cancer 86(9):1457-1464 (2002).Chang, A., et al., Anticancer Res. 21(5):3147-3152 (2001).Diamandis, E.P., et al., Trends Endocrinol. Metab. 11(2):54-60 (2000).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.